Current Edition


Salvat heads to regulators with phase 3 data on ocular steroid

Salvat is gearing up to launch an ocular corticosteroid treatment for inflammation and pain in cataract surgery patients after finishing phase 3 trials and starting …

Continue Reading →

Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache

Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster …

Continue Reading →

New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma

Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled …

Continue Reading →
clostridium difficile

Discontinuation of Sanofi’s C. difficile Vaccine Program presents an opportunity for Pfizer and Valneva, observes GlobalData

On December 1 2017, Sanofi Pasteur announced its intention to discontinue the Phase III development program for its Clostridium difficile vaccine. The vaccine was on …

Continue Reading →

Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports

Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates and fewer …

Continue Reading →